Ipsen to Acquire Memo Therapeutics for Up to EUR700M

Summary Ipsen will acquire Memo Therapeutics for up to EUR700M including EUR200M upfront, adding potravitug, a Phase 2 monoclonal antibody for BK polyomavirus-associated nephropathy in kidney transplant recipients. What Happened The acquisition strengthens Ipsen’s rare disease portfolio and supports a planned pivotal Phase 2/3 study…